ArticleJournal of clinical practice and research2024
Responses of Helper T Cell Subsets at Diagnosis and After Discharge in Patients with Non-Severe COVID-19: A Prospective Observational Study.
Article in Journal of clinical practice and research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus responsible for Coronavirus Disease 2019 (COVID-19), elicits a strong immune response similar to that seen in other viral infections. The predominant cell type in this immune response also influences the disease prognosis. This study, conducted between 2022 and May 2023, aimed to evaluate the transcription factors and cytokine expressions of Th (helper T) cell subsets at the time of diagnosis and after discharge in patients with non-severe COVID-19. Materials and Methods: Forty-eight patients with non-severe COVID-19 were included in the study. Transcription factor and cytokine expressions of Th cell subsets were evaluated using the quantitative polymerase chain reaction (qPCR) method, and the results were compared at the time of diagnosis and after discharge. Results: It was determined that the cytokines and transcription factors of T helper 1 (Th1) cells (T-box expressed in T cells [T-bet], 2.71-fold, p<0.001; Interferon-gamma [IFN-γ], 1.42-fold, p=0.010) and T helper 17 (Th17) cells (RAR-related orphan receptor gamma [RORγt], 1.06-fold, p=0.946; Interleukin-22 [IL-22], 1.01-fold, p=0.599) decreased, whereas the expression of T helper 2 (Th2) cells (GATA binding protein 3 [GATA3], 2.56-fold, p<0.001; Interleukin-4 [IL-4], 1.34-fold, p=0.012; Interleukin-5 [IL-5], 1.02-fold, p=0.649; Interleukin-13 [IL-13], 2.06-fold, p=0.0119) and regulatory T (Treg) cells (Forkhead box P3 [FoxP3], 3.56-fold, p<0.001; Transforming growth factor-beta [TGF-β], 1.03-fold, p=0.670; Interleukin-10 [IL-10], 1.40-fold, p=0.010) increased. Conclusion: Our study in non-severe COVID-19 patients demonstrated significant changes in the transcription factor and cytokine expressions of Th cell subsets at the time of diagnosis compared to discharge. We think that even if the patients do not exhibit severe clinical and laboratory findings, Th cell immune responses may be strong, warranting careful consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.